New immune drug targets common cancer mutation in early trial

NCT ID NCT06778863

Recruiting now Disease control Sponsor: Clasp Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mutation. The study aims to find the safest dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLSP-1025 (a drug that helps immune cells attack cancer cells with a specific p53 mutation)
What this could lead to: If successful, this could point toward a new treatment option for several hard-to-treat cancers that have a specific p53 mutation.
What could go wrong: This is an early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal adenocarcinoma head and neck squamous cell carcinoma lung cancer lung neoplasm metastatic malignant neoplasm Neoplasm Metastasis ovarian cancer pancreatic adenocarcinoma prostate cancer Squamous Cell Carcinoma of Head and Neck urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BLADDER CANCER BREAST CANCER COLORECTAL ADENOCARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA LUNG CANCER METASTATIC SOLID TUMOR OVARIAN CANCER PANCREATIC ADENOCARCINOMA PROSTATE CANCER UNRESECTABLE SOLID TUMOR

Contacts and locations

Show contact details

Locations

Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27701, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Arizona Cancer Center
RECRUITING

Tucson, Arizona, 85719, United States
The University of Chicago Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
USC - Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

Contact Email: •••••@•••••
University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Kentucky Markey Cancer Center
RECRUITING

Lexington, Kentucky, 40536, United States
University of Miami - Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.